"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Parkinson Disease

Interventions

DRUG

PBF-509

DRUG

Placebo

Trial Locations (2)

CIM Sant Pau - I.I.B. Sant Pau, Barcelona

Palobiofarma S.L. (molecule owner), Mataró